bpc-157 fda approval status warning FDA's Overreach on Compounded Peptides fda warning bpc-157 not approved

Improve Red Blood Cell Production Deficiency can cause megaloblastic anemia, leading to fatigue, weakness, and pale skin

the new blood vessels could inadvertently feed microscopic cancer cells

This means that every time you think you are using 1mg of Tirzepatide, you are only using 0.5mg, which can throw off your entire experiment

Populations who should not use BPC-157: Pregnant or breastfeeding individuals (no safety data), anyone with a history of cancer (theoretical concern given pro-angiogenic mechanisms), individuals taking anticoagulants (some animal data suggest effects on platelet aggregation pathways), and anyone without access to sterile technique for injection preparation

Disclaimer: BPC-157 and TB-500 are not FDA-approved medications

Press Release - SL-NAD Human Trial Results - final.ashx Accessed March 2025